Paul Chamberlain is an Ophthalmology physician. OpenAlex indexes 33 publications with 1,150 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
101 W 8th Ave
Spokane, WA 992042307
Telephone
509-474-3020Provider last certified this registry record 15 Jun 2022.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20254 payments
- Bausch & Lomb Americas Inc.Program year20253 payments
- Alcon Vision LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
75.2%Prostaglandin Analog31%Latanoprost88%Lumigan5%Travoprost3%Tafluprost2%Bimatoprost1%Part D<11 patientsCarbonic Anhydrase Inhibitor20.6%Dorzolamide-Timolol67%Dorzolamide Hcl15%Simbrinza8%Brinzolamide7%Acetazolamide Er3%Part D<11 patients+ 7 more classes in this area
Anti-infectives
10.9%Fluoroquinolone Antibacterial9.7%Moxifloxacin100%Part D≥231 patientsMacrolide0.6%Erythromycin100%Part D≥21 patients+ 1 more class in this area
Cardiovascular
7%Beta blocker7%Timolol Maleate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Eye growth and myopia progression following cessation of myopia control therapy with a dual‐focus soft contact lens
Optometry and Vision Science
2025 - Six‐year cumulative treatment effect and treatment efficacy of a dual focus myopia control contact lens
Ophthalmic and Physiological Optics
2023 - Six years of wearer experience in children participating in a myopia control study of MiSight® 1 day
Contact Lens and Anterior Eye
2023 - Myopia Control Dose Delivered to Treated Eyes by a Dual‐focus Myopia‐control Contact Lens
Optometry and Vision Science
2023
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”